Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Nov 08, 2022 4:46pm
137 Views
Post# 35083453

RE:RE:RE:RE:RE:One part of strategy is right

RE:RE:RE:RE:RE:One part of strategy is rightWe who have that option really are not that fortunate as the info obtained has not always been accurate. That is not to say they necessarily lie to us but they get things wrong too. It is hard to know most of the time whether something is a intentional lie or not, but whatever the case may be, the info gained is hardly guaranteed to be helpful. There is a very good chance it will lead you to the wrong conclusion given the inescapable bias management has to tilt what they say in a favorable way.
Biobob wrote: Maybe... market hates uncertainty and they provide lots of it.  Like SPCEO said it's unconfortable unless you are one of the few ones that get one on ones with management.


<< Previous
Bullboard Posts
Next >>